Literature DB >> 18239678

Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration.

F Gelisken1, F Ziemssen, M Voelker, K U Bartz-Schmidt, W Inhoffen.   

Abstract

PURPOSE: To analyse retinal pigment epithelial (RPE) tears following single administration of intravitreal bevacizumab for neovascular age-related macular degeneration (AMD) during early follow-up.
METHODS: Interventional, retrospective, non-comparative case series included 397 patients (409 eyes) of the 746 consecutive patients that met the eligibility criteria. Standardized visual acuity testing, fluorescein angiography, and optical coherence tomography were performed. Data collected included status of the fellow eye, previous treatment, subtypes of choroidal neovascularization (CNV), size and composition of the lesion. Multiple linear regression modelling was used to explore the effect of baseline parameters on the RPE tears. Primary end point was occurrence of RPE tears within 6 weeks after therapy.
RESULTS: Fifteen of the 409 eyes (3.6%) developed RPE tear (95% confidence interval: 2.2-6.0, odds ratio: 26.3). The statistical modelling showed significant association between RPE tear and occult without classic CNV/predominantly haemorrhage vspredominantly/minimal classic CNV (P=0.019), as well as medium or large (>4 disc area) vssmall size of the total lesion (P=0.038). Previous treatment and status of the fellow eye did not statistically influence the risk of RPE tears.
CONCLUSIONS: An RPE tear can develop in up to 3.6% of eyes with neovascular AMD following single administration of intravitreal bevacizumab in a short-term follow-up. Medium and large lesion size and occult without classic and predominantly haemorrhagic subtype of CNV were important predictive factors. Preoperative assessment of the lesion characteristics may help in identifying the risk of individual patients with neovascular AMD before intravitreal bevacizumab treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239678     DOI: 10.1038/sj.eye.6703098

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  14 in total

Review 1.  [Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options].

Authors:  A Lommatzsch
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

2.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  Pigment epithelial tears after ranibizumab injection in polypoidal choroidal vasculopathy and typical age-related macular degeneration.

Authors:  Joo Youn Shin; Moonjung Choi; Byunghoon Chung; Suk Ho Byeon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-07       Impact factor: 3.117

4.  Immediate loss of vision due to retinal pigment epithelial tear after anti-angiogenesis treatment of pigment epithelial detachment.

Authors:  Kurt Spiteri Cornish; Robert Harvey
Journal:  Digit J Ophthalmol       Date:  2011-08-18

5.  Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats.

Authors:  Yan Lu; Nan Zhou; Xiao Huang; Jin-Wei Cheng; Feng-Qian Li; Rui-Li Wei; Ji-Ping Cai
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

6.  Retinal Pigment Epithelium Tear.

Authors:  Aleksandra V Rachitskaya; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2014-12-06

7.  [Serous vascularized pigment epithelial detachment in exudative AMD. Morphological typing and risk of tears in the RPE].

Authors:  B Lehmann; B Heimes; M Gutfleisch; G Spital; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

Review 8.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.

Authors:  Juan-Carlos Gutiérrez-Hernández; Sean Caffey; Walid Abdallah; Phillip Calvillo; Roberto González; Jason Shih; Jeff Brennan; Jenna Zimmerman; Juan-Carlos Martínez-Camarillo; Anthony R Rodriguez; Rohit Varma; Arturo Santos; Gisela Sánchez; Mark Humayun
Journal:  Transl Vis Sci Technol       Date:  2014-07-01       Impact factor: 3.283

10.  Direct Blood Flow Measurements in a Free RPE-Choroid Graft with Phase-Resolved Doppler OCT.

Authors:  Elsbeth J T van Zeeburg; Boy Braaf; Matteo G Cereda; Jan C van Meurs; Johannes F de Boer
Journal:  Transl Vis Sci Technol       Date:  2015-01-13       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.